Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
By J. Smolen, M. Schoels, Norihiro Nishimoto, F. Breedveld, Gerd R. Burmester, M. Dougados, Paul Emery, Gianfranco Ferraccioli, C. Gabay, A. Gibofsky and 25 more. Annals of the Rheumatic Diseases, 2012
14,291 citations recorded by the source corpus.
Background Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion. Methods Preparation of this document involved international experts in RA treatment and RA patients. A systematic literature search was performed that focused on TCZ and other IL6-pathway inhibitors in RA and other diseases. Subsequently, incorporating available published evidence and expert opinion, the steering committee and a broader expert committee (both including RA patients) formulated the current consensus statement. Results The consensus statement covers use of TCZ as combination- or monotherapy in various RA populations and includes clinical, functional and structural aspects. The statement also addresses the second approved indication in Europe JIA and non-approved indications. Also early phase trials involving additional agents that target the IL-6 receptor or IL-6 were evaluated. Safety concerns, including haematological, hepatic and metabolic issues as well as infections, are addressed likewise. Conclusions The consensus statement identifies points to consider when using TCZ, regarding indications, contraindications, screening, dose, comedication, response evaluation and safety. The document is aimed at supporting clinicians and informing patients, administrators and payers on opportunities and limitations of IL-6 pathway inhibition.
Subfields: Hematology, Immunology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/ba7ec4a6fb0214f4f3f5053e4c871324a4669d74
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
Citations in the corpus
- The Use of Google Trends in Health Care Research: A Systematic Review (2014, methodology): “Conventional tools to assess bias are largely limited to randomized trials and observational studies and are not readily applicable to studies using Google Trends data, which is observational in nature but does not involve individual research participants.[10,11] Therefore, we attempted to address t”
- Are healthcare workers’ intentions to vaccinate related to their knowledge, beliefs and attitudes? a systematic review (2013, methodology): “Taking these concerns into account, we have attempted to be as rigorous as possible in the methodology of this review [34].”
- Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies (2019, neutral): “Epidemiology (MOOSE; eTable 2) [21] guidelines.”
- Prognostic Significance of Tumor-infiltrating T-cells in Ovarian Cancer: a Meta-analysis (2011, methodology): “We followed guidelines for the design, analysis, and reporting of meta-analyses of observational studies published by the MOOSE group [10].”
- REPORTING GUIDELINES FOR META‐ANALYSIS IN ECONOMICS (2020, methodology): “Although other guidelines for conducting and reporting meta-analyses have been offered (Stroup et al., 2000; Higgins and Green, 2017; Appelbaum et al., 2018), none other than Stanley et al. (2013) have explicitly considered the type of empirical evidence typically found in applied econometric…”
- Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis (2020, background): “Although systematic reviews and metaanalyses usually include randomized clinical trials (RCTs) and aim to provide a more precise estimate of the effect of a treatment or risk factor for disease, also have been extensively used, especially during the last decades, to synthesized observational studies”